These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 6214730)
21. The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. Francis DA; Grundy D; Heron JR J Neurol Neurosurg Psychiatry; 1986 Jan; 49(1):87-9. PubMed ID: 3958735 [TBL] [Abstract][Full Text] [Related]
22. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Hersch SM; Gevorkian S; Marder K; Moskowitz C; Feigin A; Cox M; Como P; Zimmerman C; Lin M; Zhang L; Ulug AM; Beal MF; Matson W; Bogdanov M; Ebbel E; Zaleta A; Kaneko Y; Jenkins B; Hevelone N; Zhang H; Yu H; Schoenfeld D; Ferrante R; Rosas HD Neurology; 2006 Jan; 66(2):250-2. PubMed ID: 16434666 [TBL] [Abstract][Full Text] [Related]
23. Sodium valproate in chorea. Br Med J; 1976 Dec; 2(6051):1562. PubMed ID: 137765 [No Abstract] [Full Text] [Related]
24. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Shoulson I; Goldblatt D; Charlton M; Joynt RJ Ann Neurol; 1978 Sep; 4(3):279-84. PubMed ID: 152602 [TBL] [Abstract][Full Text] [Related]
25. gamma-Aminobutyric acid receptors in normal human brain and Huntington disease. Van Ness PC; Watkins AE; Bergman MO; Tourtellotte WW; Olsen RW Neurology; 1982 Jan; 32(1):63-8. PubMed ID: 6275305 [TBL] [Abstract][Full Text] [Related]
26. Elevation of brain gamma-aminobutyric acid in the mouse by L-2,4-diaminobutyric acid. Shuter ER; Robins E Trans Am Neurol Assoc; 1974; 99():49-51. PubMed ID: 4156893 [No Abstract] [Full Text] [Related]
27. Therapeutic failure of GABA agonist treatment in Huntington's disease. Waddington JL; Cross AJ Neurology; 1984 May; 34(5):702. PubMed ID: 6231490 [No Abstract] [Full Text] [Related]
28. Erythrocyte membrane alterations in Huntington disease: effects of gamma-aminobutyric acid. Butterfield DA; Braden ML; Markesbery WR J Supramol Struct; 1978; 9(1):125-30. PubMed ID: 215837 [TBL] [Abstract][Full Text] [Related]
29. [GABA system in the brain. Possible clinical and pharmacological aspects]. Gulmann NC Ugeskr Laeger; 1978 Jul; 140(28):1667-70. PubMed ID: 151363 [No Abstract] [Full Text] [Related]
30. Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Tell G; Böhlen P; Schechter PJ; Koch-Weser J; Agid Y; Bonnet AM; Coquillat G; Chazot G; Fischer C Neurology; 1981 Feb; 31(2):207-11. PubMed ID: 6258106 [TBL] [Abstract][Full Text] [Related]
31. Uptake and release of GABA and GABA in Huntington's chorea [proceedings]. Iversen LL Psychopharmacol Bull; 1977 Jan; 13(1):30-1. PubMed ID: 138147 [No Abstract] [Full Text] [Related]
32. [Toxic action of kainic acid as a model of Huntington chorea and epilepsy (review)]. Levin SL; Sytinskiĭ IA Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(5):754-63. PubMed ID: 6224382 [No Abstract] [Full Text] [Related]
34. Rational approaches to the pharmacotherapy of chorea. Chase TN Res Publ Assoc Res Nerv Ment Dis; 1976; 55():337-50. PubMed ID: 137504 [No Abstract] [Full Text] [Related]
35. Minocycline safety and tolerability in Huntington disease. Huntington Study Group Neurology; 2004 Aug; 63(3):547-9. PubMed ID: 15304592 [TBL] [Abstract][Full Text] [Related]
36. [Neurotransmitters in Huntington chorea (review)]. Barkhatova VP; Larskiĭ EG Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):444-50. PubMed ID: 2581405 [No Abstract] [Full Text] [Related]
37. Vitamin E in treatment of Huntington's chorea. Caro AJ; Caro S Br Med J; 1978 Jan; 1(6106):153. PubMed ID: 145890 [No Abstract] [Full Text] [Related]
38. Quantitative autoradiography of neurotransmitter receptors in Huntington disease. Penney JB; Young AB Neurology; 1982 Dec; 32(12):1391-5. PubMed ID: 6292789 [TBL] [Abstract][Full Text] [Related]